RenovoRx announces initial results in PK sub study within TIGeR-PaC trial

RenovoRx announced initial results from a pharmacokinetic, PK, substudy within the phase III un-blinded randomized control TIGeR-PaC clinical trial to be presented at the 2023 ASCO Gastrointestinal, ASCO GI, Cancers Symposium this week. The TIGeR-PaC clinical trial is evaluating intra-arterial administration of gemcitabine using the proprietary RenovoRx Trans-Arterial Micro-Perfusion platform for targeted treatment of Locally Advanced Pancreatic Cancer, LAPC. The substudy provides clinical support that RenovoTAMP may increase local drug delivery and thus concentration at the tumor site while decreasing the debilitating side effects often associated with systemic intravenous delivery, which is the current standard of care. "Intra-arterial Gemcitabine vs IV Gemcitabine PK Substudy in Patients with Locally Advanced Pancreatic Cancer," presented by Amer H. Zureikat, MD, et al., evaluates RenovoTAMP for IA delivery of gemcitabine directly into tumors for higher local drug concentration and decreased systemic drug concentration and associated side effects. The PK substudy evaluates a sample of LAPC patients participating in the TIGeR-PaC study and demonstrates that the cohort had an average greater than 50% reduction in systemic drug exposure with IA delivery of gemcitabine using RenovoTAMP when compared with IV administration. The substudy concludes that RenovoTAMP may increase local gemcitabine concentration, which may be beneficial in decreasing gemcitabine-related systemic side effects. Five TIGeR-PaC clinical sites participated in this substudy. Three additional clinical data abstracts presented by researchers at ASCO GI with data from the induction phase of the TIGeR-PaC study help to advance the science behind pancreatic cancer.